BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 11, 2026
See today's BioWorld MedTech
Home
» Funding to be used for host of trials: Cancer genomics firm Inivata pulls in $42M in series A funding
To read the full story,
subscribe
or
sign in
.
Funding to be used for host of trials: Cancer genomics firm Inivata pulls in $42M in series A funding
Jan. 27, 2016
By
Nuala Moran
LONDON – Inivata Ltd. has raised £31.5 million (US$42.2 million) in a series A round, to advance the commercialization of its circulating tumor DNA liquid biopsy technology.
Medical technology
